Remote platelet function testing using P-selectin expression in patients with recent cerebral ischaemia on...

Area of Science:

• Neuroscience
• Pharmacology
• Cardiology

Background:

• Antiplatelet agents are crucial for reducing recurrent cerebral ischemia.
• Treatment resistance to antiplatelet drugs like clopidogrel affects patient outcomes.
• Understanding clopidogrel insensitivity is key to improving stroke prevention.

Purpose of the Study:

• To determine the proportion of patients resistant to clopidogrel.
• To investigate the link between clopidogrel insensitivity and recurrent cerebrovascular events.

Main Methods:

• Recruited patients with recent non-cardioembolic ischemic stroke or TIA on clopidogrel.
• Assessed platelet function via remote measurement of P-selectin (CD62P) expression.
• Collected data on recurrent vascular events at least 90 days post-enrollment.

Main Results:

• 11.3% of patients demonstrated resistance to clopidogrel.
• No significant association was found between clopidogrel resistance and recurrent ischemic events.
• Aspirin resistance was not observed in patients taking both aspirin and clopidogrel.

Conclusions:

• Remote platelet function assessment using P-selectin is a feasible method.
• A notable percentage of patients show resistance to clopidogrel.
• Current findings do not establish a significant link between clopidogrel resistance and event recurrence.